Table 3 Sensitivity analysis: incremental cost-effectiveness ratio (ICER) of HPV vaccination* in Estonia, model estimates.
ICER € per QALYs | |
|---|---|
Base case | 4889 |
Screening characteristics | |
Under hypothetical improved cervical screening program** | 6167 |
Vaccine characteristics | |
Assuming no HPV 6/11 protection | 5771 |
Duration of protection = 20 years | 8090 |
Vaccination characteristics | |
Low vaccine coverage (70%) | 4444 |
High vaccine coverage (95%) | 5212 |
Costs characteristics | |
Cost of diagnosis and treatment +20% | 4744 |
Cost of diagnosis and treatment −20% | 5037 |
Cost of vaccine - 10% | 4351 |
Cost of vaccine + 10% | 5454 |
Health utility values | |
Cost per life year saved (no quality of life adjustments) | 6746 |
Discount rate | |
Discount rate 0% | 1517 |
Discount rate 5% | 11148 |